Literature DB >> 32867810

Impact of negative air pressure in ICU rooms on the risk of pulmonary aspergillosis in COVID-19 patients.

Philippe Ichai1, Faouzi Saliba2, Patricia Baune3, Asma Daoud2, Audrey Coilly2, Didier Samuel2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32867810      PMCID: PMC7458783          DOI: 10.1186/s13054-020-03221-w

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
From the start of the COVID-19 epidemic, one recommendation regarding the intensive care management of COVID-19 patients concerned the infrastructure in intensive care units (ICU) and particularly the air pressure system in ICU rooms [1]. Under normal circumstances and mainly in ICUs hosting immunocompromised patients, ICU rooms are equipped with positive air room pressure in order to protect patients against infections from the surrounding environment and particularly those due to Aspergillus fumigatus (AF). This link between positive pressure rooms and a reduction in Aspergillus infection rates has been demonstrated during several studies [2]. However, these studies included numerous other associated preventive measures. The relationship between the fungal levels in the air of neutral pressure rooms and those in positive pressure rooms has not been established [3]. During the current COVID-19 pandemic, on the contrary, the recommendations have been to place intensive care rooms under negative or even normal pressure so as to protect the staff and patients healthcare. Two recent studies reported a high incidence (26.3–33%) of pulmonary aspergillosis in COVID-19 infected patients [4, 5]. This high risk of pulmonary aspergillosis was also seen in patients with severe influenza (19%). Thevissen et al. reported that the rate of influenza-associated pulmonary aspergillosis (IAPA) varied according to country and that variation in IAPA prevalence might be related to underdiagnosis due to lower use of galactomannan testing on broncho-alveolar lavage or serum in some areas [6]. In line with these recommendations, the 15 rooms of our ICU were placed under negative pressure to receive COVID-19 patients. During this change, all filters in the air conditioning unit were replaced. Two months earlier, routine air sampling had not revealed the presence of any fungal agents and our annual incidence of aspergillosis was lower than 2%. Between 23 March and 4 May 2020, 26 COVID-19 patients were admitted to our ICU (Table 1). Six of the 26 (23.1%) developed probable or proven pulmonary aspergillosis, while two were colonized by AF.
Table 1

Principal characteristics of patients with probable or proven pulmonary aspergillosis

Mean age (SD): 64 ± 9 years

Gender (n males): 18 M

ARDS due to COVID-19, n = 21

Delay between admission and the diagnosis of aspergillosis: 6.5 ± 4.2 days

Antifungal therapy: 6/6

- Isavuconazole, n = 5

- Voriconazole, n = 1

Alive: 4/6 patients (67%)

Principal characteristics of patients with probable or proven pulmonary aspergillosis Mean age (SD): 64 ± 9 years Gender (n males): 18 M ARDS due to COVID-19, n = 21 Delay between admission and the diagnosis of aspergillosis: 6.5 ± 4.2 days Antifungal therapy: 6/6 - Isavuconazole, n = 5 - Voriconazole, n = 1 Alive: 4/6 patients (67%) Air cultures from the rooms occupied by the first four infected patients revealed the presence of AF. No colonies of AF were found on the surfaces in rooms or in the air of stepdown rooms (same building, same geographical orientation, two floors up) that were sampled at the same time and were being operated under unventilated rooms. During the crisis, no building projects were being carried out anywhere near the ICU. Checks on accessible sections of the room ventilation circuits did not identify any reservoir of contamination. After surface disinfection, the negative air pressure in the rooms was raised on two successive occasions, ultimately reaching a pressure of 1.2 ± 1.5 Pa. From that time on, the levels of AF in room air fell in spectacular fashion (0–2 CFU/m3) (Fig. 1).
Fig. 1

Chronology of Aspergillus infections among COVID-19 patients in the ICU and environmental mycological results. After lowering to a negative pressure in the 15 ICU rooms, probable or proven pulmonary aspergillosis developed in six patients and Aspergillus colonization in two patients. Analysis of the air in the three of four rooms tested, before any corrective measures, were positive for Aspergillus fumigatus. Despite decreasing the negative air pressure to − 5 Pa, high levels of Asp. fumigatus remained positive in the room air. When the air pressure in the rooms was brought to around 0 Pa, the number of Aspergillus colonies markedly diminished and then became undetectable. Since then, no patient developed Asp. fumigatus infection. AF, Asp. fumigatus; AF (+), presence of Asp. fumigatus; AF (−), absence of Asp. fumigatus

Chronology of Aspergillus infections among COVID-19 patients in the ICU and environmental mycological results. After lowering to a negative pressure in the 15 ICU rooms, probable or proven pulmonary aspergillosis developed in six patients and Aspergillus colonization in two patients. Analysis of the air in the three of four rooms tested, before any corrective measures, were positive for Aspergillus fumigatus. Despite decreasing the negative air pressure to − 5 Pa, high levels of Asp. fumigatus remained positive in the room air. When the air pressure in the rooms was brought to around 0 Pa, the number of Aspergillus colonies markedly diminished and then became undetectable. Since then, no patient developed Asp. fumigatus infection. AF, Asp. fumigatus; AF (+), presence of Asp. fumigatus; AF (−), absence of Asp. fumigatus All infected patients received antifungal therapy and 4 out of 6 are alive. Prophylactic antifungal therapy was administered to all other patients. Since then, no further cases of aspergillosis have been recorded. Our results demonstrate that implementing negative pressure in ICU rooms could be the source of air contamination by Aspergillus and thus increase the risk of opportunistic infections. A switch to neutral or slightly positive pressure in the rooms, combined with standard environmental cleaning protocols and prophylactic antifungal treatments, enabled the eradication of aspergillus from the air in these rooms. One hypothesis regarding contamination was a spread of dust from the plenum spaces in false ceilings which “might” have been moved during successive adjustments to high/low/neutral pressure and could have infiltrated via unsealed parts of the ceiling. Close mycological screening of COVID-19 infected patients (biomarkers and mycological diagnosis) and regular controls of air quality are highly recommended.
  6 in total

1.  A 2-year comparative study of mold and bacterial counts in air samples from neutral and positive pressure rooms in 2 tertiary care hospitals.

Authors:  Laura Ryan; Niall O'Mara; Sana Tansey; Tom Slattery; Belinda Hanahoe; Akke Vellinga; Maeve Doyle; Martin Cormican
Journal:  Am J Infect Control       Date:  2018-01-04       Impact factor: 2.918

Review 2.  Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence?

Authors:  H Humphreys
Journal:  J Hosp Infect       Date:  2004-02       Impact factor: 3.926

3.  Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19.

Authors:  Alexandre Alanio; Sarah Dellière; Sofiane Fodil; Stéphane Bretagne; Bruno Mégarbane
Journal:  Lancet Respir Med       Date:  2020-05-20       Impact factor: 30.700

Review 4.  Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.

Authors:  Jason Phua; Li Weng; Lowell Ling; Moritoki Egi; Chae-Man Lim; Jigeeshu Vasishtha Divatia; Babu Raja Shrestha; Yaseen M Arabi; Jensen Ng; Charles D Gomersall; Masaji Nishimura; Younsuck Koh; Bin Du
Journal:  Lancet Respir Med       Date:  2020-04-06       Impact factor: 30.700

5.  International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe.

Authors:  Karin Thevissen; Cato Jacobs; Michelle Holtappels; Mitsuru Toda; Paul Verweij; Joost Wauters
Journal:  Crit Care       Date:  2020-03-11       Impact factor: 9.097

6.  COVID-19 associated pulmonary aspergillosis.

Authors:  Philipp Koehler; Oliver A Cornely; Bernd W Böttiger; Fabian Dusse; Dennis A Eichenauer; Frieder Fuchs; Michael Hallek; Norma Jung; Florian Klein; Thorsten Persigehl; Jan Rybniker; Matthias Kochanek; Boris Böll; Alexander Shimabukuro-Vornhagen
Journal:  Mycoses       Date:  2020-05-15       Impact factor: 4.377

  6 in total
  9 in total

1.  Mixed invasive fungal infections among COVID-19 patients.

Authors:  Vanya Singh; Amber Prasad; Prasan Kumar Panda; Manjunath Totaganti; Amit Kumar Tyagi; Abhinav Thaduri; Shalinee Rao; Mukesh Bairwa; Ashok Kumar Singh
Journal:  Curr Med Mycol       Date:  2021-12

2.  COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report.

Authors:  Ayako Shimada; Shinnosuke Ohnaka; Kosumi Kubo; Masanao Nakashima; Atsushi Nagai
Journal:  Cureus       Date:  2022-04-02

Review 3.  Invasive aspergillosis in coronavirus disease 2019: a practical approach for clinicians.

Authors:  Frederic Lamoth
Journal:  Curr Opin Infect Dis       Date:  2022-04-01       Impact factor: 4.915

4.  Air Sampling for Fungus around Hospitalized Patients with Coronavirus Disease 2019.

Authors:  Yi-Chun Chen; Yin-Shiou Lin; Shu-Fang Kuo; Chen-Hsiang Lee
Journal:  J Fungi (Basel)       Date:  2022-06-30

Review 5.  The role of SARS-CoV-2 immunosuppression and the therapy used to manage COVID-19 disease in the emergence of opportunistic fungal infections: A review.

Authors:  Nahid Akhtar; Atif Khurshid Wani; Surya Kant Tripathi; Ajit Prakash; M Amin-Ul Mannan
Journal:  Curr Res Biotechnol       Date:  2022-08-03

Review 6.  A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA).

Authors:  Simon Feys; Maria Panagiota Almyroudi; Reinout Braspenning; Katrien Lagrou; Isabel Spriet; George Dimopoulos; Joost Wauters
Journal:  J Fungi (Basel)       Date:  2021-12-11

7.  Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure.

Authors:  Francesco Fortarezza; Annalisa Boscolo; Federica Pezzuto; Francesca Lunardi; Manuel Jesús Acosta; Chiara Giraudo; Claudia Del Vecchio; Nicolò Sella; Ivo Tiberio; Ilaria Godi; Annamaria Cattelan; Luca Vedovelli; Dario Gregori; Roberto Vettor; Pierluigi Viale; Paolo Navalesi; Fiorella Calabrese
Journal:  Mycoses       Date:  2021-07-04       Impact factor: 4.931

Review 8.  Airway recommendations for perioperative patients during the COVID-19 pandemic: a scoping review.

Authors:  Sylvain Boet; Daniel I McIsaac; Manoj M Lalu; Alexa Lynn Grudzinski; Billy Sun; MengQi Zhang; Agnes Crnic; Abdul H Djokhdem; Mary Hanna; Joshua Montroy; Laura V Duggan; Gavin M Hamilton; Dean A Fergusson
Journal:  Can J Anaesth       Date:  2022-02-02       Impact factor: 6.713

9.  COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States.

Authors:  Anastasia I Wasylyshyn; G Rostyslaw Wasylyshyn; Kathleen A Linder; Marisa H Miceli
Journal:  Mycopathologia       Date:  2021-06-18       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.